Announcement • Nov 14

+ 1 more update

Lexeo Therapeutics, Inc. Provides Update on Cardiac Portfolio

Lexeo Therapeutics, Inc. provided business updates across its portfolio of programs. Business and Program Updates: LX2006 for the Treatment of FA Cardiomyopathy: Regulatory Update: Alignment on key elements of accelerated development pathway following a Type C meeting with the U.S. Food and Drug Administration (FDA): Increase in frataxin expression and reduction in left ventricular mass index (LVMI) as co-primary registrational endpoints to support accelerated approval; Target levels including 10% reduction in LVMI and 40% frataxin positive area as measured by immunohistochemistry (IHC); Histology-based measurement of frataxin and cardiac MRI as acceptable measurement tools; Use of secondary endpoints including left ventricular wall thickness and troponin as supportive measures of efficacy; Enrollment of participants with elevated LVMI in pivotal trial; Final dose selection and size of registrational trial alignment expected in 2025 guided by cohort 3 cardiac biopsy results; RMAT Designation: In October 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for LX2006 for the treatment of FA cardiomyopathy based on interim clinical data announced in July 2024. RMAT designation is granted for regenerative medicines that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition with preliminary clinical evidence that indicates the therapy has the potential to address unmet medical needs. This designation permits sponsor companies to have early and frequent interactions with the FDA through BLA filing. Completion of Enrollment of SUNRISE-FA: Completion of enrollment of SUNRISE-FA Phase 1/2 trial, with four participants administered LX2006 in cohort 3. To date, eight participants have received LX2006 in SUNRISE-FA and eight participants have received LX2006 in an ongoing Weill Cornell-sponsored investigator-initiated trial. International Congress for Ataxia Research (ICAR) Presentation: Lexeo will share new cardiac biopsy data from one participant in cohort 2 and functional scales from three participants in the Lexeo-sponsored SUNRISE-FA trial at ICAR on November 15, 2024. One Newly Reported Cardiac Biopsy Result from Cohort 2: Observed a 35% increase in frataxin protein expression from baseline as measured by liquid chromatography mass spectrometry (LCMS), and a 279% increase from baseline in frataxin positive area from 7% pre-treatment to 26% post-treatment from baseline as measured by IHC. The post-treatment average across cohort 1 and cohort 2 biopsy samples is 44% frataxin positive area as measured by IHC. Newly Reported Functional Results from July 2024 Interim Data Set: All three participants had more than a 5-point improvement in the Kansas City Cardiomyopathy Questionnare-12 (KCCQ-12) and at least a 1-point improvement in the modified Friedreich Ataxia Rating Scale (mFARS) as of their latest visit (2 participants at 12-months, and 1 participant at 6-months). LX2006 Continues to be Generally Well Tolerated: LX2006 has been generally well tolerated across both SUNRISE-FA and Weill Cornell investigator-initiated trials to date. One possibly treatment-related Grade 2 event of asymptomatic myocarditis was observed one year after dosing in a participant with multiple comorbidities and history of flu-like symptoms prior to diagnosis, which may have been a contributing factor. A biopsy was performed six weeks after initial diagnosis and results were negative for myocarditis; participant remains asymptomatic. LX2020 for the Treatment of PKP2-ACM: Completed enrollment of cohort 1 (n=3) of HEROIC-PKP2 Phase 1/2 trial. LX2020 has been generally well tolerated to date, with no evidence of complement activation and no unexpected safety events or toxicities associated with study drug observed. Anticipate proceeding to cohort 2 following data review by independent data safety and monitoring board. Initial data from cohort 1 with a focus on safety and biodistribution as assessed via cardiac biopsy expected in late First Quarter /early Second Quarter 2025. LX1001 for the Treatment of APOE4-associated Alzheimer’s Disease: Announced positive interim Phase 1/2 results for LX1001 at the CTAD conference. LX1001 was generally well tolerated to date across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA). A dose and time-dependent increase in neuroprotective APOE2 expression was observed in all participants with ongoing durability at 12 months, and reductions in CSF tau biomarkers and tau PET were seen in a majority of participants.

Announcement • Feb 06

Lexeo Therapeutics, Inc. Strengthens Clinical Development Leadership with New Executive Appointments

Lexeo Therapeutics, Inc. announced new executive appointments to lead the evolution of the company’s pipeline into late-stage clinical development. Sandi See Tai, MD, has been promoted to Chief Development Officer. Prior to Lexeo, Dr. See Tai was VP & Development Head for Rare Disease at Pfizer, responsible for setting the Rare Disease internal portfolio strategy and delivering its clinical development portfolio of investigational products and in-line assets. She served as the Medicine Team Lead for clinical programs across multiple therapeutic areas including Rare Cardiovascular, Neurology, Renal and Pulmonary disease areas. During her tenure, Dr. See Tai led the late-stage clinical development program of tafamidis for ATTR cardiomyopathy (ATTR-ACT), which achieved global regulatory approvals, and the Phase 3 LMNA dilated cardiomyopathy clinical program. In addition to late-stage clinical development, Dr. See Tai was responsible for strategic clinical planning for early-stage development candidates such as those for other genetic cardiomyopathies and Duchenne Muscular Dystrophy. With almost 20 years of experience in the pharmaceutical industry, Dr. See Tai held multiple roles of increased scope and responsibility across Global Medical Affairs in Transplantation at Wyeth Pharmaceuticals before moving into clinical development at Pfizer. Prior to joining the pharmaceutical industry, Dr. See Tai was Assistant Professor of Pediatrics at Drexel University College of Medicine and Attending Physician in Pediatric Nephrology at St. Christopher’s Hospital for Children, Philadelphia, where she also completed her General Pediatrics residency and Pediatric Nephrology fellowship. She received her MD from Tufts University School of Medicine, Boston. Eric Adler, MD, has been appointed Chief Medical Officer & Head of Research. As a pioneer and thought leader in cardiovascular gene therapy, Dr. Adler formerly served as Chief Scientific Officer at Lexeo since joining in 2022. Prior to this role, Dr. Adler served as Professor of Medicine, head of the Heart Failure Section, Director of the Strauss Center for Cardiomyopathy, and the Czarina and Humberto S. Lopez Chancellor’s Endowed Chair in Cardiology at the University of California, San Diego (UCSD). Dr. Adler’s work has led to the development of a novel cardiovascular gene therapy candidate entering late-stage clinical development. His research is focused on the study and treatment of cardiomyopathy, and he has published over 100 papers in peer reviewed journals on the topic. Dr. Adler is currently an associate editor of Circulation Hearth Failure and has served on leadership, grant review, and guidelines committees for the American Heart Association, the Heart Failure Society of America, the International Society of Heart and Lung Transplant, and the National Institute of Health. Dr. Adler earned his medical degree from the Boston University School of Medicine. Rajiv Patni, MD, has been appointed Senior Advisor to the Chief Executive Officer and Board of Directors of Lexeo. Dr. Patni was formerly Chief Research and Development Officer at Reata Pharmaceuticals (acquired by Biogen for $7.3 billion), a commercial-stage biopharmaceutical company that received approval for Skyclarys, the first FDA-approved therapy for Friedreich’s ataxia. Prior to this role, Dr. Patni served as Chief Medical Officer at several public, small-cap, commercial-stage biopharmaceutical companies including Portola (acquired by Alexion for $1.4 billion) and Global Blood Therapeutics (acquired by Pfizer for $5.4 billion) and at those companies, Dr. Patni oversaw the clinical studies leading to the approvals of Andexxa and Oxbryta. Dr. Patni joined these companies at inflection points in their research and development growth trajectories and significantly supported their successful acquisitions. Over his 24-year industry tenure in global product development, Dr. Patni has contributed to the development of 21 new chemical entities in several therapeutic areas including cardiology, diabetology, hepatology, neurology, and benign hematology. His experience in fostering successful teams from 35 to 250 colleagues contributed to the approval of 11 medicines from the US FDA, EMA, and other regulatory agencies. The recent approvals include medicines for several rare diseases such as pulmonary arterial hypertension, advanced Parkinson’s disease, sickle cell disease, and Friedrich’s ataxia. Dr. Patni received his MD from the Mount Sinai School of Medicine in New York City as part of an accelerated BS/MD Program. He completed his internal medicine residency and adult cardiology fellowship at the Albert Einstein College of Medicine, also in New York City, where he continued as an attending physician-scientist before joining the biopharmaceutical industry. Jenny R. Robertson has been appointed Chief Business and Legal Officer. Ms. Robertson formerly served as Chief Legal and Administrative Officer at Lexeo, leading legal, human resources, information technology, information security, and facilities strategies and activities. Prior to Lexeo, Ms. Robertson served as Chief Counsel to Pfizer’s Oncology Business Unit and held other senior legal roles including Chief Counsel for Pfizer’s Rare Disease Business Unit, where she led the global legal team for five years. Across positions at Pfizer, Ms. Robertson counseled clients on a range of business and legal matters including commercialization, disclosure, business development, alliance management, clinical development, intellectual property issues and litigation. Before joining Pfizer in 2010, Ms. Robertson spent 10 years in private practice with a large international law firm in New York and Washington, D.C., engaged in complex commercial litigation with a healthcare focus. Ms. Robertson holds a Bachelor of Arts Degree in Political Science from Southern Illinois University and a J.D. from the Georgetown University Law Center, where she co-founded and served as Editor-in-Chief of The Georgetown Journal of Gender and the Law.

Total Shareholder Yield	-71.5%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Segment	Dividend Yield
Company (LXEO)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.5%
Analyst forecast (LXEO) (up to 3 years)	n/a

Data	Last Updated (UTC time)
Company Analysis	2026/06/09 15:50
End of Day Share Price	2026/06/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Brian Skorney	Baird
Kristen Kluska	Cantor Fitzgerald & Co.
Yevgeniya Livshits	Chardan Capital Markets, LLC

Lexeo Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation

Insufficient new directors

Lexeo Therapeutics, Inc., Annual General Meeting, Jun 25, 2026

Lexeo Therapeutics, Inc. Announces Stepping Down of Dr. Adler as Head of Research, Effective February 1, 2026

Lexeo Therapeutics Announces Executive Appointments

Lexeo Therapeutics Announces Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy Caused by Mutations in the FDA

Lexeo Therapeutics: Behind The Rebound

Lexeo Therapeutics, Inc. has filed a Follow-on Equity Offering.

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?

Lexeo Therapeutics, Inc. Announces CFO Changes

Lexeo Therapeutics, Inc. Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) dropped from Russell Microcap Growth Index

Lexeo Therapeutics, Inc. announced that it expects to receive $79.999971 million in funding from a group of investors

Lexeo Therapeutics, Inc., Annual General Meeting, Jun 26, 2025

Lexeo Therapeutics, Inc. Announces Positive Interim Data Across All Dose Cohorts of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Deliver On Growth Plans?

Lexeo Therapeutics, Inc. Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics, Inc. Provides Update on Cardiac Portfolio

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics, Inc. Appoints Tim Van Hauwermeiren to Its Board of Directors

We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely

CEO & Director notifies of intention to sell stock

Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors

Lexeo Therapeutics, Inc. announced that it expects to receive $94.999833 million in funding from Braidwell LP, Novo Holdings A/S, Adage Capital Management, L.P., RA Capital Management, L.P., Surveyor Capital Management, Eventide Asset Management, LLC

Lexeo Therapeutics, Inc. Strengthens Clinical Development Leadership with New Executive Appointments

Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's

Lexeo Therapeutics, Inc. has completed an IPO in the amount of $100.00001 million.

High number of new and inexperienced directors

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources